Brainstorm Cell Therapeutics Reports Q2 2025 Financial Results with Improved Net Loss

Brainstorm Cell Therapeutics Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $5.77 million, or $0.77 per share, compared to a net loss of $5.94 million, or $1.35 per share, for the same period in 2024. The company’s operating expenses for the first half of 2025 totaled $5.66 million, slightly up from $5.46 million in the prior year. The increase in expenses was primarily driven by higher research and development costs, which rose to $2.42 million from $1.88 million, reflecting increased clinical activities and payroll expenses. General and administrative expenses decreased to $3.24 million from $3.57 million, attributed to reduced payroll and consulting costs.

As of June 30, 2025, Brainstorm reported total assets of $2.57 million, a significant increase from $1.83 million at the end of 2024. This growth was largely due to an increase in cash and cash equivalents, which rose to $0.82 million from $0.19 million. The company’s liabilities decreased to $8.62 million from $9.60 million, primarily due to a reduction in operating lease liabilities. The total stockholders’ deficit improved to $6.06 million from $7.76 million, indicating a positive shift in the company’s financial position.

Strategically, Brainstorm has faced challenges, including a delisting notification from Nasdaq due to non-compliance with minimum shareholder equity requirements. As a result, the company’s shares began trading on the OTCQB Venture Market on July 18, 2025. Despite these challenges, Brainstorm has continued to advance its clinical programs, including the NurOwn® treatment for amyotrophic lateral sclerosis (ALS). The company has recently signed a Letter of Intent with Minaris Advanced Therapies for the manufacturing of NurOwn® for its upcoming clinical trials.

Operationally, Brainstorm has maintained a workforce of 29 employees, with most senior management based in the United States. The company is actively engaged in clinical trials and has made significant progress in its research and development efforts. However, it continues to face uncertainties regarding its ability to raise additional capital to support ongoing operations and clinical development. The company’s management has indicated that it will explore various funding options, including public and private sales of common stock, to meet its financial needs moving forward.